Press Releases and Blog
Blog
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
ICYMI: New Survey Finds Overwhelming Majority of Employers Value a Wide Range of Pharmacy Benefit Company Contract Options
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you
Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy
Press Releases
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, released a new episode, “Understanding Prescription Drug Rebates.” The podcast episode, hosted by
New Data Reveal a Stable Independent Pharmacy Market
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the
Congressional Budget Office Confirms The Insulin Act Increases Health Care Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act
Groundbreaking Research Highlights Invaluable Role of Pharmacy Benefit Managers
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “The Value of Pharmacy Benefit Management”
PCMA Applauds Biden Administration Action to Stop Drug Manufacturer Patent Abuses, Lower Prescription Drug Costs
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug
PCMA Statement on “The Pharmacy Benefit Manager Transparency Act”
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on today’s vote in the Commerce Committee on
Big Pharma Returns with Self-Serving Policies Already Rejected by Congress
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of
A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Robust U.S. Biosimilar Market Will Encourage Competition and Lower Prescription Drug Costs for Patients
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play
94 Percent Of The Drug Dollar Is Retained By Drug Manufacturers, Drug Wholesalers, And Pharmacies
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug
Big Pharma’s Pay-For-Delay Keeps More Affordable Options From Entering The Market, Keeping Drug Prices High
In case you missed it, a new article in The Atlantic explains how big drug companies commonly use an anti-competitive tactic, “pay-for-delay,” to prevent more affordable options from entering the marketplace.
Drug Companies Possess Complete Autonomy On List Prices
The evidence is clear: prescription drug rebates negotiated by pharmacy benefit companies with drug companies are not correlated with drug list prices, which are set
PCMA President And CEO Explains Critical Value Of Pharmacy Benefit Companies On Capitol Hill
In case you missed it, PCMA President and CEO JC Scott testified before the U.S. House Education and the Workforce Committee Subcommittee on Health, Employment, Labor,
Business Groups and Employers Express Support for Preserving Their Contracting Flexibility
In case you missed it, business groups and individual employers from across the country signed the below letter to Congress expressing support for preserving their
Bank Of America Survey Confirms Pharmacy Benefit Market Is Competitive, Transparent, And Delivering Value For Employers
Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed
Employers Hire Pharmacy Benefit Companies To Manage Growing Rx Drug Costs
Fact: Employers are under no obligation to hire pharmacy benefit companies, but a vast majority of employers work with pharmacy benefit companies. Recent findings from